Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I disagree. Speculation and innovation is that nature of making strides in technology. In the words of some other famous man...
"no progress was ever made by those that were satisfied by the status quo. We must grow and expand in order to break the confines of our own imprisonment."
Just because the pps flounders doesn't mean its a scam. Just because you don't think their science is any good, doesn't mean its a scam.
How long have you been following the story? There is so much more to it than just that. The 10000 shares is of a non-operating entity with intellectual property, They are planning a reverse merger with a much larger privately owned corporation of unkown value, and deep pockets. PARD shareholders will retain 35% of the new company. In order to stay listed on nasdaq market, the share price has to come back above a certain level, and a reverse split will bring the share price to that level. Cry dilution if you like, but that's not what is going on here. The Intellectual property of Poniard is valuable, they just didn't have the money burn that it requires to get their products through the regulatory process. Now they have a new partner, and the partner has the resources that is necessary to get things moving. Not only that, but the new partner desires to be publicly traded. 35% Is much greater than average. The new partner has an entire pipeline of product candidates of its own as well. Things are looking up for good old Poniard Pharmaceuticals.
IGXT is breaking out! in Anticipation of FDA approval!
IGXT is breaking out, and it is gaining momentum! In Anticipation of FDA approval!
Igxt is running in anticipation of FDA Approval!
IGXT is running in anticipation of FDA approval!
Hey Matt, IGXT is breaking out nicely on Merit. They have upcoming FDA Decisions. Where do you think the resistance and support levels should be?
I wonder if you would consider doing a chart on this one for me, so I know what to look for?
I appreciate the help.
TIA
Also, here is a link to their pipeline information.
http://content.stockpr.com/intellectns/files/clinicaltrials.jpg
It says: Big Pharma A, and Big Pharma B.
And this one links to an article that tells about the ex-pfizer researcher on board at ILNS.
http://biomedreports.com/2010090753008/former-big-player-at-wyeth-and-pfizer-has-joined-intellect-neurosciences.html
This is a little bit older report from Biomedreports.com
I think it is releveant in the current discussion.
Four Big Pharmas Bet Big on Intellect Neurosciences' Platform to Treat Alzheimer's Disease
Breaking News
Wednesday, 14 July 2010 04:02
LOS ANGELES, CA--(Marketwire - July 14, 2010) - Intellect Neurosciences (OTCBB: ILN ), a very small, publicly traded micro-cap company which was, until just recently, in debt and struggling to survive, is now in line for a chunk of the profits from the $20+ billion Alzheimer's Disease space.
A newly published report reveals for the first time how Pfizer, Wyeth, Elan, and Johnson and Johnson have all focused on attacking the illness by licensing and devloping a protected platform technology from Intellect Neurosciences.[/b]
"We believe that we have an approach that has the high potential to succeed because it targets a very primary point in Alzheimer's disease," said Dr. Daniel G. Chain Ph.D., Chairman and Chief Scientific Officer of ILNS. "We also believe that drugs which have the potential to slow down or arrest Alzheimer's disease are on the horizon now. We're much closer than we have been, previously."
Chain's father, Ernst Chain M.D. discovered how penicillin could be used as a dramatically effective, life-saving antibiotic. For his work, the elder Chain shared the Nobel Prize with the better-known Dr. Alexander Fleming and Chain's head of department, Howard Florey in the 1940s.
Now, some of the biggest pharmaceutical companies in the world may help Dr. Chain become known as the scientist who discovered what may prove to be not just a treatment for the symptoms -- but a way to stop or even prevent -- Alzheimer's disease.
"I'll never forget it -- the date was November 10, 1996," Chain explains."I woke up on this unsuspecting Sunday morning with an idea for a potential therapy for Alzheimer's Disease.It just crystallized in my mind on that morning -- a way to prevent the accumulation of the toxin that floats in brain fluid."
Details about the sizable license agreements, which are scheduled to pay Intellect a mid-single digit royalty upon reaching certain milestones in the development and patent process, had never been published until now. Bound by non-disclosure agreements and strict corporate gag orders, not even Intellect Neurosciences has been allowed to publicly discuss key details of the agreements to their own investors.
"The company today has a very special value proposition," says Chain. "We have royalty bearing licenses. Some of the details are confidential but someone could potentially connect their own dots by looking closely through our filings with the SEC."
According to BioMedReports, as the company eliminated and converted their debt, they issued millions of new shares, but a vast majority of those shares are held by insiders who are subject to a one year lockup that expires on April 23, 2011 and prevents them from selling their shares.
According to the latest statistics, in America alone, 5.3 million people have Alzheimer's and those numbers are expected to double in the next thirty years.
Thus far, the U.S. Food and Drug Administration has approved only two types of medications for Alzheimer's and both only seek to treat the cognitive symptoms of the disease, not the disease itself.
Investors can find the full report and read details about these developments at BioMedReports.Com
Biotech investors interested in accessing the news portal's complete database of clinical trials and upcoming FDA decisions can access that information here:
http://biomedreports.com/fda-calendar/fda-calendar.html
About BioMedReports.Com BioMedReports.com is a news portal covering the biomedical news and financial sector. BioMedReports is not paid or compensated to report the news and developments of publicly traded companies.
I thnk you are off on your numbers. The first settlement figure by my account is $.0278 per share
on 8/10 closing price was .039
on 8/9 closing price was .04
on 8/8 closing price was .04
average of the 3 = .0396
70% of that = .0278
I figure that "20 trading days preceeding the installment date" does not include the installment date.
That's old news.
I think it will be approved because the US Military wants it approved.
Probably about the spin offs.
Oh!...okay!.... I'm not confessing what I thought it was!
I'd be buying more right now if I wasn't out of money.
What is "21 BM" ?
I looked at another one and in that same spot it said
"(Name of registrant as specified in charter)"
Makes me think it was some sort of typo. I still think there is better news coming.
WOW! I wonder how I could have missed that. It is very peculiar looking!
I haven't seen a connection between Nexcen and Univec either.
congratulations!
have you waited through any of these before?
How long do you think before we hear something?
www.incorporate.com
Mailing address is: Same as the new filing?
The Company Corporation
2711 Centerville Road, Suite 400
Wilmington, DE 19808
These ones also...
http://www.corpamerica.com/
https://www.cscglobal.com/global/web/csc/home
Found this...
http://www.corporationwiki.com/Delaware/Wilmington/2711-Centerville-Rd-Ste-400-Wilmington-DE-19808-a104512.aspx
I guess it looks like some incubator or something. You should see what google maps says....!
Here's another article with a picture. Now we know what he looks like.
http://books.google.com/books?id=JsYR13clarsC&pg=PA40&lpg=PA40&dq=Health+Resources,+Inc.+dr.+David+L.+Dalton&source=bl&ots=fxTVG3pjNP&sig=3fncotaNW4FbQkSCKig9tEpG1gU&hl=en&ei=S3uwTeGtL_PZiAKr282vBg&sa=X&oi=book_result&ct=result&resnum=8&sqi=2&ved=0CFQQ6AEwBw#v=onepage&q=Health%20Resources%2C%20Inc.%20dr.%20David%20L.%20Dalton&f=false
I agree.
Thanks for the info.
Here's another project he's involved in.
http://www.umbiopark.com/biopark/park-leadership.aspx
Check this....Same address as pinksheets...#43 in 2009 and #34 in 2010 on the list of the nations top 100 African American-owned businesses.
http://www.blackenterprise.com/2009/05/13/43-health-resources-inc/
G-filer? What does that mean?
I pay perfectly good money for the subscriber section of biomedreports. I am offended that you take it and post it publicly. RPC Rocks! & so does BMR!
What is "LOLOLOL" ?
News out...RS takes affect next Tuesday.
So, tell me, in the best interest of securing my confidence in my investment in ILNS, where are you getting this information? Can you post reference links? Be honest here, is there some research that you're looking at that I haven't or are you speculating and theorizing? Links are much appreciated.
It is a two pronged approach. I've seen you write this garbage before. prong one is to prevent the buildup of neurotoxins with the vaccine. the other prong is to break down the existing tartar buildup and flush it out. I think they're on the right track, and I think they will be first to market, and I think they will be best in class.
How about..."Administrative Complications?" That means relatively the same thing. Even still...I think you're stressing out about it too much. Relax!
I think you are on track with this one.
I think you are off base with this one, Taki. Malone Bailey is a bigwig accounting firm, with a small army of accountants. I firmly believe that Troy will be on time. There is absolutely ZERO chance that he is up to no good. With positive earnings on the books, there's no need to do anything dishonest. No...there's reason to expand and grow, and to earn more money next time.
they 've filed an extension every quarter for the last year. There's nothing to worry about. If it was out of character, I would worry, but it's not...it's run of the mill. Earning comes out, and this one will righteously uptrend.
some people trying to shake loose cheapies from weak hands...what's up with the same typos in different people's posts?
Patience here is key.
so did Microsoft and Comcast